A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

NCT01502423 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
61
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AbbVie (prior sponsor, Abbott)